Sign Out
Use in patients with dihydropyrimidine dehydrogenase deficiency may cause toxicity; therefore the administration should be cautioned.
Because alternating therapy of methotrexate and fluorouracil is highly risky, the patients should be under the direct supervision of a qualified physician who is experienced in the use of cancer chemotherapeutic agents.
Severe hepatic impairment including hepatitis may occur. Hepatic function tests should be monitored closely. If any symptoms occur, the administration should be discontinued and appropriate therapy instituted.
Continue with Google